Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
VORTIOXETINA Y DISFUNCIÓN SEXUAL ASOCIADA CON OTROS ANTIDEPRESIVOS
Journal of Clinical Medicine 13(12):1-7
Difundido en siicsalud: 5 ago 2024
EFICACIA A LARGO PLAZO DE LOS FÁRMACOS ANTIPSICÓTICOS EN ADULTOS CON ESQUIZOFRENIA
World Psychiatry 22(2):315-324
Difundido en siicsalud: 10 sep 2024

LA QUETIAPINA TIENE EFICACIA ANTIDEPRESIVA

(especial para SIIC © Derechos reservados)
La eficacia antidepresiva de la quetiapina se demuestra sobre la base de información clínica y farmacodinámica. La autorización del uso de quetiapina en pacientes con trastornos bipolares, como monoterapia o complemento de otras drogas, se debió en una primera instancia a la eficacia observada en estudios a doble ciego, aleatorizados y controlados.
Autor:
Chiara Rovera
Columnista Experto de SIIC

Institución:
Fondazione IRCCS Ospedale Maggiore Policlinico


Artículos publicados por Chiara Rovera
Coautores
Chiara Di Pace* Silvia Paletta* Alessandra Reggiori* Valentina Ciappolino* Massimo Carlo Mauri** Alfredo Carlo Altamura** 
Médica, Fondazione IRCCS Ospedale Maggiore Policlinico, Milán, Italia*
Médico, Fondazione IRCCS Ospedale Maggiore Policlinico, Milán, Italia**

Resumen
La presente revisión muestra la eficacia antidepresiva de la quetiapina (QTP) sobre la base de información farmacodinámica y clínica. La QTP se encuentra aprobada por la FDA estadounidense para el tratamiento de los pacientes con esquizofrenia y trastornos bipolares. En particular, la QTP se encuentra indicada para el tratamiento de los episodios depresivos asociados con el trastorno bipolar; los episodios maníacos o mixtos asociados con el trastorno bipolar tipo I, como monoterapia o como adyuvante del litio o del divalproato; así como en la terapia de mantenimiento de los pacientes con trastorno bipolar tipo I en combinación con el litio o el divalproato. Por otro lado, la European Medicines Agency (EMEA) indicó el uso de QTP en pacientes con esquizofrenia y para el tratamiento y la prevención de los pacientes con trastorno bipolar: en particular para el tratamiento de los episodios maníacos moderados a graves y de los episodios de depresión mayor en pacientes con trastorno bipolar; también para la prevención de las recurrencias de los episodios maníacos o depresivos en pacientes con trastorno bipolar y antecedentes de respuesta a la QTP. La QTP también puede utilizarse como complemento del tratamiento de los pacientes con episodios de depresión mayor que presentan una respuesta subóptima a otros antidepresivos. La autorización del uso de QTP en pacientes con trastornos bipolares, como monoterapia o como complemento de otras drogas, se debió en primer lugar a la eficacia observada en estudios a doble ciego, aleatorizados y controlados. Además, muchos síntomas de depresión se deben a la disminución de la neurotransmisión dopaminérgica en la corteza prefrontal (CPF). Se cree que el metabolito activo de la QTP, la norquetiapina, facilita la liberación de dopamina en la CPF debido al antagonismo 5HT2A y 5HT2C y resulta útil para aliviar los síntomas depresivos en pacientes con trastornos del estado de ánimo.

Palabras clave
quetiapina, metabolito activo, antidepresivos, norquetiapina, antipsicóticos


Artículo completo

(castellano)
Extensión:  +/-15.04 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Abstract
This review shows the antidepressants efficacy of quetiapine (QTP) on the basis of pharmacodynamics and clinical data. QTP is approved by the american FDA for the treatment of schizophrenia and bipolar disorders. In particular QTP is indicated for the treatment of depressive episodes associated with bipolar disorder, manic or mixed episodes associated with bipolar I disorder as either monotherapy or adjunct therapy to lithium or divalproex and in maintenance treatment of bipolar I disorder as adjunct therapy to lithium or divalproex. On the other hand European Medicines Agency (EMEA) indicates the use of QTP in schizophrenia and in the treatment and prevention of bipolar disorder: in particular in the treatment of moderate to severe manic episodes in bipolar disorder and major depressive episodes in bipolar disorder; prevention of recurrence of manic or depressed episodes in patients with bipolar disorder who previously responded to QTP. QTP can also be used as add-on to ongoing treatment for major depressive episodes in patients with major depressive disorder who have had sub-optimal response to treatment with other antidepressants. The licensing of QTP in bipolar disorders either as monotherapy or adjunctive to other medications, was firstly due to its efficacy in double blind, randomized, controlled trials. Moreover many symptoms of depression result from decreased dopamine neurotransmission in the prefrontal cortex (PFC). It is believed that the active metabolite of QTP, norquetiapine, with its 5HT2A and 5HT2C antagonism facilitates dopamine release in PFC and is instrumental in relieving the depressive symptoms in mood disorders.

Key words
quetiapine, active metabolite, antidepressants, noquetiapine, antipsychotic


Full text
(english)
para suscriptores/ assinantes

Resumen del idioma nativo
Questa review discute l’efficacia della quetiapina (QTP), come antidepressivo, sulla base dei dati disponibili di farmacodinamica e clinici. La QTP e’ un antipsicotico atipico il cui utilizzo clinico e’ stato approvato dalla Food and Drug Administration americana (FDA) nella schizofrenia e nel disturbo bipolare. In particolare la QTP e’ indicata per il trattamento degli episodi depressivi associati al disturbo bipolare e negli episodi maniacali o misti associati al disturbo bipolare I sia in monoterapia che in terapia associata ai sali di litio o all’acido valproico e nel mantenimento del disturbo bipolare come terapia aggiuntiva ai sali di litio o all’acido valproico. D’altro canto l’Agenzia per i Farmaci Europea (EMEA) ha indicato l’uso della QTP nella schizofrenia e nel trattamento e prevenzione del disturbo bipolare: in particolare nel trattamento degli episodi moderati e severi degli episodi maniacali nel disturbo bipolare e negli episodi depressivi maggiori nel disturbo bipolare che aveva risposto in precedenza alla QTP. La QTP puo’ essere anche utilizzata in aggiunta al trattamento dell’episodio depressivo maggiore nei pazienti affetti da disturbo depressivo maggiore che avevano avuto una risposta sub-ottimale al trattamento con antidepressivi. L’autorizzazione all’uso della QTP nel disturbo bipolare sia in monoterapia che in associazione ad altri farmaci era inizialmente data dalla sua dimostrazione di efficacia in studi controllati, in doppio cieco, randomizzati. Per altro, molti sintomi depressivi risultano legati ad una riduzione della trasmissione dopaminergica nella corteccia prefrontale (PFC). E’ stato dimostrato che il metabolita attivo della QTP, la norquetiapina, grazie alla sua attivita’ antagonista a livello dei recettori 5HT2A e 5HT2C, faciliti il rilascio di dopamina a livello della PFC, in tal modo risultando attiva sui sintomi depressivi nei disturbi dell’umore.

Palabras clave del idioma nativo
quetiapina, metabolita attivo, antidepressivos, norquetiapina, antipsicoticos


Artículo completo
(idioma nativo)
para suscriptores/ assinantes

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Farmacología, Salud Mental
Relacionadas: Atención Primaria, Medicina Farmacéutica, Salud Pública



Comprar este artículo
Extensión: 15.04 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Massimo Carlo Mauri, 20122, Via F. Sforza 35, Milán, Italia
Bibliografía del artículo
1. Hawkins SB, Bucklin M, Muzyk AJ. Quetiapine for the treatment of delirium. J Hosp Med 8:215-220, 2013.
2. Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs 25:803-813, 2011.
3. Plosker GL. Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. Pharmacoeconomics 30:611-631, 2012.
4. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, DeGaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relation- ship between plasma concentrations and clinical response. Clin Pharmacokinet 46(5):359-388, 2007.
5. Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin 29:813-825, 2013.
6. López-Muñoz F, Alamo C. Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry 12 (4):102, 2013.
7. Winter HR, Earley WR, Hamer- Maanson JE, Davis PC, Smith MA. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adol Psychopharmacol 18:81-98, 2008.
8. Prieto E, Micó JA, Meana JJ, Majadas S. Neurobiological bases of quetiapine antidepressant effect in the bipolar disorder. Actas Esp Psiquiatr 38(1):22-32, 2010.
9. Bakken GV, Rudberg I, Molden E, Refsum H, Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 33(2):222-226, 2011.
10. Fisher DS, Handley SA, Taylor D, Flanagan RJ. Measurement of quetiapine and four quetiapine metabolites in human plasma by LC- MS/MS. Biomed Chromatogr 26(9):1125-1132, 2012.
11. Bakken GV, Molden E, Knutsen K, Lunder N, Hermann M. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos 40(9):1778-1784, 2012.
12. Altamura AC, Moliterno D, Paletta S, Buoli M, Dell'Osso B, Mauri MC, et al. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observationa study. Clin Drug Investig 32:213-219, 2012.
13. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553-559, 2000.
14. Mundo E, Cattaneo E, Zanoni S, Altamura AC. The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder. Neuropsychiatr Dis Treat 2:139-148, 2006.
15. Rasmussen H, Ebdrup BH, Aggernaes B, Lublin H, Oranje B, Pinborg LH, et al. Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia. J Clin Psychopharmacol 33:266-269, 2013.
16. Björkholm C, Jardemark K, Marcus MM, Malmerfelt A, Nyberg S, Schilström B, et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur Neuropsychopharmacol 23:709-720, 2013.
17. Silverstone PH, Lalies MD, Hudson AL. Quetiapine and buspirone both elevate cortical levels of noradrenaline and dopamine in vivo, but do not have synergistic effects. Front Psychiatry 3:82, 2012.
18. Sümegi A. Quetiapin in bipolar disorders. Neuropsychopharmacol Hung 10:281-291, 2008.
19. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Cur Drug Targets 14:578-585, 2013.
20. Cross A J, Widzowski D, Maciag C, Zacco A, Hudzik T, Liu J, Nyberg S, Wood MW. Quetiapine and its metabolite norquetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models. Br J Pharmacol 173(1):155-166, 2016.
21. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, et al. Efficacy andtolerability of extended releasequetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 128(1-2):83-94, 2011.
22. Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson B. Quetiapine for the treatment of bipolar II depression: Analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 9(3):198-211, 2008.
23. Riedel M, Musil R, Spellmann I, Seemüller F, Möller HJ. Quetiapine XR -a retard formulation in the treatment of schizophrenia. Eur PsychiatrRev 1:70-75, 2008.
24. Peuskens J. Themanagement of schizophrenia: focus on extended release quetiapine fumarate. Neuropsychiatr Dis Treat 7:549-564, 2011.
25. Rush AJ. Combining antidepressant medications: a good idea? Am J Psychiatry 167:241-243, 2010.
26. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 71:43-64, 2011.
27. Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry 63 (12):1156-63, 2002.
28. Calabrese JR, Elhaj O, Gajwani P, Gao K. Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 66(Suppl 5):26-33, 2005.
29. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W; BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67(3):355-362, 2006.
30. Milev R, Abraham G, Zaheer. Ad-on quetiapine for bipolar depression: a 12-month open-label trial. J Can J Psychiatry 51(8):523-530, 2006.
31. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W; BOLDER Study Group. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 22(1):29-37, 2007.
32. Baune BT, Caliskan S, Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol 22(1):1-9, 2007.
33. Del Bello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 11(5):483-493, 2009.
34. Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 27(7):515-529, 2007.
35. Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, Suppes T. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 69(5):769-782, 2008.
36. Duffy A, Milin R, Grof P. Maintenance treatment of adolescent bipolar disorder: open study of the effectiveness and tolerability ofquetiapine. BMC Psychiatry 9:4, 2009.
37. Suppes T, Datto C, Minkwits M, Nordemham A, Walker C, Dato D. Effectiveness of the extended release formulation of quetiapine as monotherapy of the treatment of acute bipolar depression. J Affect Disor 121(1-2):106-15, 2010.
38. Young AH, Calabrese JR, Gustafsson U, Berk M, McElroy SL, Thase ME, Suppes T, Earley W. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipol Disord 1:10, 2013.
39. Mc Elroy S, Hevey D. Relationship between adverse early experiences, stressors, psychosocial resources and wellbeing. Child Abuse Negl 38(1):65-75, 2014.
40. Ketter TA, Brooks JO 3rd, Hoblyn JC, Holland AA, Nam JY, Culver JL, Marsh WK, Bonner JC. Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting. J Psychiatr Res 44(14):921-929, 2010.
41. Kim SJ, Lee YJ, Lee YJ, Cho SJ. Effect of quetiapine XR on depressive symptoms and sleep quality compared with lithium in patients with bipolar depression. J Affect Dis 157:33-40, 2014.
42. Spielmans GI, Berman I, Linardatos E, Rosenlicht RZ, Perry A, Tsai AC. Adjuntive atipycal antipsychotic treatment for Majior depressive disorder: a meta-analysis of depression, quality of life and safety outcomes. PoLS MED 10(3) e1001403, 2013.
43. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Dis127(1-3):19-30, 2010.
44. Bandelow B, Bauer M, Vieta E, El-Khalili N, Gustafsson U, Earley WR, Eriksson H. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry 15(2):155-66, 2014.
45. Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacology 27(1):27-39, 2012.

 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
Artículos relacionadosMás relacionadosAtículos relacionados
OLANZAPINA EN DOSIS ALTAS EN LA ESQUIZOFRENIA RESISTENTE AL TRATAMIENTO
Therapeutic Advances in Psychopharmacology 13
Difundido en siicsalud: 26 abr 2024
ANTIPSICÓTICOS ATÍPICOS EN LA ANOREXIA NERVIOSA
Plos One 18(3):1-24
Difundido en siicsalud: 15 abr 2024
ua31618